@thestockmd Hi! I came across your guest post on PIMD and was curious to dig in a bit more on day trading on your website but I believe it's currently down. Fascinated by your story as I'm in similar shoes w/ profession & interest in the market.
Stifel report has a very balanced discussion about impacts of the election on biotech along with M&A (strong October but quiet year), and other data (list of companies exploring strategic alternatives, capital markets, china, obesity, etc)
https://t.co/acxapX1FYy
Nice visualization of a key driver of pharma M&A $XBI
Total revenue loss from LOE for 2024-2028 forecasted to be >2x that of the preceding 5-year period
"Sentiment & Themes Emerging From JPM 2024"
Inaugural blog in From The Trenches from Atlas' Aimee Raleigh on the big themes and outlook for 2024.
Insightful summary of where things are.
https://t.co/vtkDVyd7FN
https://t.co/DfUNSD7lDe
@AimeeRaleigh13@atlasventure
A few years back I started a journey to learn more about biopharma and drug discovery. Here is a list of the books I have found helpful (loosely grouped by topic) with the outstanding books highlighted by (+++). Feel free to add your own recommendations, I'll keep adding mine.
Largely unreported, SEC has made an unannounced policy shift where they treat many Reverse Mergers like "shell" deSPACs (not as typical mergers), which hampers ability of newly public co to finance & locks up affiliates far longer. May materially change +/-'s for Reverse Mergers
An open letter to SEC Chair Gary Gensler
I’ve been in #Bitcoin 9 years & have been a registered & licensed securities professional for 30 years. I’m a FINRA registered principal & majority owner of an SEC registered broker.
Let’s talk SBF/ FTX, DC politics & transparency:
👇👇